FIASP
Drug
Novo Nordisk AS
Total Payments
$21.5M
Transactions
9,939
Doctors
1,498
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $59,162 | 28 | 24 |
| 2020 | $164,241 | 16 | 8 |
| 2019 | $1.3M | 427 | 55 |
| 2018 | $6.9M | 5,803 | 1,383 |
| 2017 | $13.2M | 3,665 | 51 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21.2M | 7,194 | 98.3% |
| Travel and Lodging | $170,367 | 244 | 0.8% |
| Consulting Fee | $144,863 | 34 | 0.7% |
| Food and Beverage | $53,563 | 2,208 | 0.2% |
| Education | $8,245 | 259 | 0.0% |
Payments by Type
Research
$21.2M
7,194 transactions
General
$377,036
2,745 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NN1218-4113 | Novo Nordisk AS | $7.3M | 1 |
| NN1218-4101 | Novo Nordisk AS | $5.6M | 0 |
| NN1218-4131 | Novo Nordisk AS | $4.3M | 0 |
| NN1218-3854 | Novo Nordisk AS | $3.4M | 0 |
| The efficacy and safety of faster insulin aspart (Fiasp) compared to insulin aspart as correction bo | Novo Nordisk Inc | $254,724 | 0 |
| Comparison of post-prandial glycemic control in non-critically ill hospitalized patients with type 2 | Novo Nordisk Inc | $136,507 | 0 |
| An exploratory cross-over trial comparing Fiasp Vs. Novolog in Medtronic 670G in Type 1 diabetes | Novo Nordisk Inc | $131,550 | 0 |
| NN1218-3922 | Novo Nordisk AS | $71,804 | 0 |
| NN1218-4049 | Novo Nordisk AS | $13,298 | 1 |
Top Doctors Receiving Payments for FIASP
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Diego, CA | $21.1M | 7,151 |
| , MD | Endocrinology, Diabetes & Metabolism | Bennington, VT | $64,883 | 46 |
| , M.D | Endocrinology, Diabetes & Metabolism | Rockville, MD | $48,255 | 23 |
| , MD | Pediatrics | Palo Alto, CA | $39,197 | 17 |
| , M.D | Endocrinology, Diabetes & Metabolism | Atlanta, GA | $38,009 | 15 |
| , M.D | Endocrinology, Diabetes & Metabolism | San Diego, CA | $19,774 | 8 |
| , MD | General Practice | Torrance, CA | $18,978 | 3 |
| , M.D | Endocrinology, Diabetes & Metabolism | South Burlington, VT | $13,486 | 5 |
| , MD | Pediatric Endocrinology | New Haven, CT | $11,935 | 5 |
| , M.D | Pediatrics | San Francisco, CA | $7,805 | 8 |
| , MD | Pediatric Endocrinology | Tampa, FL | $7,518 | 9 |
| , MD PHD | Internal Medicine | Boston, MA | $7,368 | 4 |
| , M.D | Specialist | Encino, CA | $6,403 | 10 |
| , M.D | Pediatric Endocrinology | New Haven, CT | $5,855 | 5 |
| , MD, MMSC | Internal Medicine | Skokie, IL | $5,804 | 5 |
| , M.D | Internal Medicine | Portland, OR | $5,794 | 5 |
| , MD | Endocrinology, Diabetes & Metabolism | Saint Louis, MO | $5,697 | 5 |
| , MD | Endocrinology, Diabetes & Metabolism | Chicago, IL | $5,684 | 6 |
| , MD | Pediatrics | Minneapolis, MN | $5,669 | 5 |
| , MBBS | General Practice | Rochester, MN | $5,643 | 5 |
| , MD | Internal Medicine | Iowa City, IA | $5,549 | 5 |
| , D.O | Hospitalist | Rochester, NY | $5,214 | 5 |
| , MD | Specialist | Pittsburgh, PA | $5,030 | 5 |
| , MD | Endocrinology, Diabetes & Metabolism | Asheville, NC | $3,420 | 11 |
| , MD | Pediatric Endocrinology | Toa Alta, PR | $2,582 | 4 |
Ad
Manufacturing Companies
- Novo Nordisk AS $20.9M
- Novo Nordisk Inc $652,342
Product Information
- Type Drug
- Total Payments $21.5M
- Total Doctors 1,498
- Transactions 9,939
About FIASP
FIASP is a drug associated with $21.5M in payments to 1,498 healthcare providers, recorded across 9,939 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk AS.
Payment data is available from 2017 to 2021. In 2021, $59,162 was paid across 28 transactions to 24 doctors.
The most common payment nature for FIASP is "Unspecified" ($21.2M, 98.3% of total).
FIASP is associated with 9 research studies, including "NN1218-4113" ($7.3M).